Development of functional therapeutic antibodies via next generation DNA sequencing and bioinformatic analysis of whole B cell antibody repertoires

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

15460.1;9 PFLS-LS

Projekttitel

Development of functional therapeutic antibodies via next generation DNA sequencing and bioinformatic analysis of whole B cell antibody repertoires

Projekttitel Englisch

Development of functional therapeutic antibodies via next generation DNA sequencing and bioinformatic analysis of whole B cell antibody repertoires

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Development of functional therapeutic antibodies via next generation DNA sequencing and bioinformatic analysis of whole B cell antibody repertoires
Abstract (Englisch)	This proposal aims at combining the expertise of Prof. Reddy's group in antibody discovery by next-generation DNA sequencing & bioinformatics with NBE-Therapeutics antibody discovery know-how, for a) the development of cancer-specific antibodies, b.) the development of optimized bioinformatic algorithms to generate 'super-humanized' antibodies, and c.) to develop a novel modular synthetic gene assembly process that enables rapid, cloning free construction of super-humanized antibodies.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Development of functional therapeutic antibodies via next generation DNA sequencing and bioinformatic analysis of whole B cell antibody repertoires

Abstract
(Englisch)

This proposal aims at combining the expertise of Prof. Reddy's group in antibody discovery by next-generation DNA sequencing & bioinformatics with NBE-Therapeutics antibody discovery know-how, for a) the development of cancer-specific antibodies, b.) the development of optimized bioinformatic algorithms to generate 'super-humanized' antibodies, and c.) to develop a novel modular synthetic gene assembly process that enables rapid, cloning free construction of super-humanized antibodies.